HIV Prevention. Recent Advances and Implications for the Caribbean
|
|
- Belinda Douglas
- 5 years ago
- Views:
Transcription
1 HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010
2 Cases Year HIV Cases AIDS Cases HIV Deaths Barbados HIV/AIDS Surveillance Report Dr.D. Babb, MOH
3 Cumulative Cases Year Cumulative HIV Cases Cumulative AIDS Cases Cumulative HIV Deaths Cumulative PLHIV Barbados HIV/AIDS Surveillance Report Dr.D. Babb, MOH
4 Why the increase in emphasis on HIV Prevention? Globally, new infections continue to outpace ART coverage: 2-3 new infections for every person started on ART Global funding for ART programs starting to level off while need continues to grow HIV Vaccine nowhere in the foreseeable future
5
6 Combination Prevention Mix of interventions applied to a given population/region should be: Evidence-based Tailored to local circumstances Know your epidemic! identify your Most At-Risk Populations (MARPs) In your country, where will the next 100 HIV infections come from?
7
8 Recent Advances in HIV Prevention PMTCT Adult Male Circumcision (AMC) Antiretroviral Therapy Topical microbicides Positive Prevention
9 Recent Advances in Biomedical Interventions for HIV Prevention PMTCT Adult Male Circumcision (AMC) Antiretroviral Therapy Topical microbicides Positive Prevention
10 Mother to Child HIV Transmission in the U.S. Over Time Slide courtesy Lynne Mofenson, MD
11 Women & Infants Transmission Study (WITS) J Acquir Immune Defic Syndr 2002 April 15;29(5):
12 Prevention, Prevention, Prevention Where are we in 2010? Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access Revision, WHO
13 From 29% in 07 to 52% in 08 - an 80% increase!
14 Year Infant Cases Maternal Factor untested, NVP HAART, poor adh. bf
15 Barriers to uptake of PMTCT interventions 15
16 Recent Advances in Biomedical Interventions for HIV Prevention PMTCT Adult Male Circumcision (AMC) Antiretroviral Therapy Topical microbicides Positive Prevention
17 Epidemiologic association between circumcision & HIV Prevalence of HIV Infection, 2007 Prevalence of Male Circumcision, 2007
18 Randomized Clinical Trials Orange Farm Township, South Africa - France - 3,274 men aged years Kisumu, Kenya - US and Canada - 2,784 men aged years Rakai District, Uganda - US - 4,996 men aged years Total: 11,054 men
19 Circumcision: Reduced HIV Infection Risk Trial Intent-to-Treat (95% CI) Orange Farm 60% (0.32,0.76) Kisumu 53% ( ) Rakai 51% (0.16, 0.72) As-Treated (95% CI) 76% ( ) 60% (O ) 55% (O.22-O.75)
20 MC Service Delivery Update, Jan 2010 Country Botswana Kenya South Africa Swaziland Zambia Zimbabwe Begin date Apr 2009 Sept 2008 Jan 2008 Jan 2008 July 2009 May 2009 No. of MC's No. of MCs Nov Dec CROI th Conference on Retroviruses and Opportunistic Infections
21 Global Recommendations Countries with high prevalence (>15%), generalized heterosexual HIV epidemics and low rates of MC should consider urgently scaling up access to MC services 13 countries identified: Botswana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe Consider ethics, communication, culture, health systems, funding, gender, comprehensive prevention strategies CROI th Conference on Retroviruses and Opportunistic Infections
22 Recent Advances in Biomedical Interventions for HIV Prevention PMTCT Adult Male Circumcision (AMC) Antiretroviral Therapy Topical microbicides Positive Prevention
23 HIV transmission rate, per coital act, by plasma viral load of source partner - Rakai HIV transmission rate (per coital act) The Lancet Volume 357, Issue 9263, 14 April 2001, Pages
24 Published online May 27, 2010 DOI: /S (10)
25 3,381 HIV-serodiscordant couples from Partners in Prevention HSV/HIV Transmission Study Published online May 27, 2010 DOI: /S (10)
26 JAMA, June 10, 2009 Vol 301, No. 22 Bull World Health Organ 2009;87:488
27 Mathematical Model: Universal ART in SA Lancet, Volume 373, Issue 9657, Pages 48-57, 3 January 2009
28 Patients (n) Reduction in New HIV Diagnoses in BC: Testing, HAART, and Community VL Period of declining new HIV diagnoses in BC coincident with increased HIV testing rates, increased uptake of antiretroviral therapy, and decrease in community viral load ( ) Decline in new HIV diagnoses despite increases in syphilis, gonorrhea, chlamydia 12,000 10, New HIV+ diagnoses (all) Censored at the time of death or move New HIV+ Diagnoses (n) HIV-1 RNA, copies/ml < ,000-49,999 50, Montaner J, et al. CROI Abstract 88LB.
29 Das M, et al. CROI Abstract 33.
30 Das M, et al. CROI Abstract 33.
31 Just to meet the minimal W.H.O. guidelines, donations would have to treble instead of going flat.
32 Recent Advances in Biomedical Interventions for HIV Prevention PMTCT Adult Male Circumcision (AMC) Antiretroviral Therapy Topical microbicides Positive Prevention
33 Topical Microbicides Urgent need for prevention method that women can control Multiple prior products promising in theory, disappointing in clinical trials CAPRISA 004: tenofovir gel
34 CAPRISA 004: 1% Tenofovir Microbicide Gel for Prevention of HIV in Women Randomized, placebo-controlled, double-blind, proof-of-concept study conducted at 2 sites in South Africa HIV-uninfected women, at high risk of HIV, 2 vaginal sex acts within 30 days of screening (N = 889)* 1% Tenofovir Gel (n = 445) Placebo Gel (n = 444) Study continued until 92 HIV infections observed *N = 889 enrolled and eligible subjects from screened population of 2160 subjects. Common causes of exclusion included HIV infection (n = 536), failure to return for further evaluation (n = 142), no sexual activity (n = 132), coenrollment in a separate study (n = 135), pregnancy (n = 51). Gel applied using BAT 24 regimen: 1 gel dose up to 12 hrs before sex; 1 gel dose as soon after sex as possible within 12 hrs after sex; maximum of 2 doses to be used within 24-hr period. Abdool Karim Q, et al. Science DOI: /science Abdool Karim Q, et al. AIDS Abstract TUSS0202.
35 Incidence Rate (Infections/100 PY) CAPRISA: Reduced HIV Incidence With Tenofovir vs Placebo Gel Tenofovir gel associated with decrease in HIV incidence [1] 50% decrease at 12 mos 39% decrease at 30 mos Tenofovir Placebo Tenofovir Efficacy vs Levels of Adherence Adherence Level, % n No. of Infections Efficacy, % > < P =.007 P = cervicovaginal fluid tenofovir concentrations associated with HIV seroconversion [2] No HIV resistance to tenofovir in patients infected while using gel Use of tenofovir gel also associated with 51% decrease in HSV-2 infection [3] Mo 12 Mo Abdool Karim Q, et al. Science DOI: /science Kashuba A, et al. AIDS Abstract TUSS Abdool Karim S, et al. AIDS Abstract TUSS0204.
36 What Next After CAPRISA 004?
37 Recent Advances in Biomedical Interventions for HIV Prevention PMTCT Adult Male Circumcision (AMC) Antiretroviral Therapy Topical microbicides Positive Prevention
38 Positive Prevention Addressing HIV prevention with people aware of positive serostatus Addressing the need not to transmit HIV to others (spouses, family, children, partners) Integrating and prioritizing prevention as part of care of PLWH
39 Recommendations for Incorporating HIV Prevention into HIV Medical Care Developed by CDC, HRSA, NIH, HIVMA, with evidence-based approach Apply to medical care of all HIV-infected adolescents and adults Intended for those providing medical care to HIV-positive persons CDC/HRSA/NIH/IDSA Recommendations 39
40 What are the Recommendations? Medical providers can substantially affect HIV transmission when they screen for risk behaviors identify and treat other STDs communicate prevention messages discuss sexual and drug-use behavior positively reinforce changes to safer behavior refer patients for services (substance abuse treatment) facilitate partner notification, counseling, and testing CDC/HRSA/NIH/IDSA Recommendations
41 State of the Art Evidence-based Interventions Condom and lubricant promotion and distribution Review of 62 studies from sub-saharan Africa concluded that interventions promoting condoms can significantly increase levels of self-reported condom use in some populations. HIV testing and counseling Most HIV positive persons who know their status will reduce their risk behaviors to protect their sexual and injection partners.
42 EBI cont d Sexually transmitted infections screening and treatment STI control programs reduce STIs in commercial sex workers and their clients; evidence of STI control in reducing HIV among sex workers remains mixed. HIV care and treatment Drug using populations Substance abuse treatment, including medication assisted therapy Access to sterile syringes and safe disposal of injection equipment Other populations Male circumcision
43 EBI cont d Peer education and outreach When accompanied by risk reduction counseling and supplies provision (condom, bleach kits) is effective in reducing sexual and/or drug-using risk behaviors Significantly associated with increased levels of HIV knowledge, reduced STI prevalence, increased condom use, and reduced IDU equipment sharing. Risk reduction counseling Can have a positive impact on IDU sexual risk behaviors Decreases STI or HIV among sex workers
44 HIV Prevention in the Caribbean Implications for implementation
45 HIV Prevention in the Caribbean Know your epidemic Where will the next 100 infections come from? Expand coverage of interventions that work: Ensure broad availability of PMTCT services Streamline the PMTCT Cascade, aggressively track mothers who fall through the cracks Lobby for expansion of ART coverage?
46 HIV Prevention in the Caribbean Increase the proportion of individuals who know their status AND enroll in care Opt-out testing, PITC Strengthen referral links, f/u on those who fail to follow through on referrals Public Messaging Decrease Stigma & Discrimination especially among health care workers!
47 HIV Prevention in the Caribbean Train clinicians in proven Positive Prevention interventions but appropriately tailored to local context Continue to promote condoms, ABC Anticipate arrival of tenofovir gel but when? Other approaches?
48 Extra slides
49 Some examples Domestic International
50 For example EPPEC Outcomes Provider-led interventions led to significantly greater reduction in sexual risk at 12 months compared to the assessment only group. Brief risk assessment and provider-led interventions appear to have the greatest effect on reduction in sexual risk among patients seen in clinical settings.
51 Impact of MC Scale-up PLoS Medicine 2009 doi: /journal.pmed g001 CROI th Conference on Retroviruses and Opportunistic Infections
52 Almost Three years later What Progress has been made??? March 2007 Montreux Meeting WHO/UNAIDS Recommendations 2010 CROI th Conference on Retroviruses and Opportunistic Infections
53 Risk of HIV Transmission by VL & ART Use AIDS 2009, 23:
54
55 Where can clinicians have an impact?
56 WHO Progress Report 2009
57 Cost and Impact of MC Scaling up of MC to reach 80% of adult and newborn males in 14 African countries by 2015: Could prevent more than 4 million adult HIV infections over 15 years ( ) Could result in cost savings of US$20.2 billion between with an overall investment of approx *US$ 4 billion Would require almost 12 million MCs to be performed in the peak year, 2012 Source (* adapted): USAID/HPI (2009) The Potential Cost and Impact of Expanding Male Circumcision in Eastern and Southern Africa CROI th Conference on Retroviruses and Opportunistic Infections
58 Botswana MC Program Costs and Cost Savings (Estimates) US$ (Million) US$ (Million) Cum cost Cum Saving 15 Annual cost Annual saving Adapted from: USAID/HPI (2009) The Potential Cost and Impact of Expanding Male Circumcision in Botswana CROI th Conference on Retroviruses and Opportunistic Infections
59 Progress made on Male Circumcision to end 2009 Male circumcision prevalence at country level, 2006 Kenya Policy, strategy, Training, QA, expanded service delivery, M&E Rwanda Situation analysis, pilot service delivery in military South Africa, Zimbabwe Situation analysis, draft policy, pilot sites Namibia Draft policy, draft communications strategy, draft M&E Lesotho Situation analysis, policy development underway, draft strategy Uganda Situation analysis, policy development Tanzania, Mozambique, Malawi Situation analysis, pilot sites Zambia Policy note, Strategy, national and regional trainings Botswana Situation analysis, strategy, communications, training, expanded service delivery, M&E Swaziland Policy, strategy and implementation plan, QA CROI th Conference on Retroviruses and Opportunistic Infections
60 Oral Pre- and Post-exposure prophylaxis Oral TDF +/- FTC given to high-risk populations (e.g CSWs), either daily or intermittently
61
HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationHIV Prevention in US Women
HIV Prevention in US Women Sally L. Hodder M.D. Sally L. Hodder MD Professor of Medicine December 1, 2010 24, 2010 Overview Epidemiology of HIV in US women HIV testing Antiretroviral i treatment as HIV
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationFAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030
Evidence informed, responsive and sustainable care FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030 Alti Zwandor UNAIDS Country Director Maseru, Lesotho 9 December
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationSexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012
Sexual and Reproductive Health and HIV Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012 Global estimates of HIV-(2009) People living with HIV 33.3 million [31.4 35.3
More informationAccelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges
Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges George Siberry, MD, MPH OGAC Senior Technical Advisor for Pediatrics March, 2016 Compared to Adults, Children (
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationGlobal Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA, PhD (c) Director, Global Plan Secretariat www.zero-hiv.org
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationHIV: A global perspective on epidemiology, diagnosis and prevention
HIV: A global perspective on epidemiology, diagnosis and prevention Margaret McLees, M.D., DTMH Instructor, Division of Infectious Diseases Denver Health University of Colorado November 13, 2012 Outline
More informationADOLESCENTS AND HIV:
Elizabeth Glaser Pediatric AIDS Foundation Until no child has AIDS. Photo by Eric Bond/EGPAF, 2015 ADOLESCENTS AND HIV: PRIORITIZATION FOR ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION PROGRAMS, ADVOCACY
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationTo provide you with the basic concepts of HIV prevention using HIV rapid tests combined with counselling.
Module 2 Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs Purpose Pre-requisite Modules Learning Objectives To provide you with the basic concepts of HIV prevention using HIV rapid
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationInvesting for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS
Investing for Impact Prioritizing HIV Programs for GF Concept Notes Lisa Nelson, WHO Iris Semini, UNAIDS Top 5 Lessons Learned 1 2 3 4 5 Prioritize within the allocation amount Separate above allocation
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS Scaling up Paediatric HIV Care Treatment in resource limited settings Dr Chewe Luo MMed(Paed); MTropPaed; PhD UNICEF Health Section Programme Division
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationUpdate on PMTCT. African Health Profession Regulatory Collaborative for Nurses and Midwives. Johannesburg, Republic of South Africa, June 18-22, 2012
PMTCT Update Update on PMTCT Margarett Davis, MD, MPH Chief, Maternal and Child Health Branch Division of Global HIV/AIDS Centers for Disease Control and Prevention (CDC) African Health Profession Regulatory
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationThe Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT
The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT Peter McDermott Managing Director, CIFF 19 th Board meeting, Geneva 6 th May 2009 Investment Criteria Measurable...change
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationFrom Africa to Georgia: What We Have Learned From the Treatment for All Initiative
From Africa to Georgia: What We Have Learned From the 90-90-90 Treatment for All Initiative Carlos del Rio, MD Professor of Global Health Rollins School of Public Health Professor of Medicine Emory University
More informationHIV Drug Resistance Regional Update Eastern & Southern African Region
HIV Drug Resistance Regional Update Eastern & Southern African Region Dr R Banda, IST/ESA Dr F Cham, IST/ESA Dr RG Vaz, WHO AFRO HIVDR Steering Committee Meeting, Geneva 11-12 November 2009 1 Presentation
More informationHIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS
POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES JULY 2014 Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationA smart and doable investment
90-90-90 A smart and doable investment As of December 2013 Adults and children living with HIV Adults and children newly infected Adult & child deaths due to AIDS 35.0 million [33.2 million 37.2 million]
More informationUNAIDS 2018 THE YOUTH BULGE AND HIV
UNAIDS 218 THE YOUTH BULGE AND HIV UNAIDS Explainer THE YOUTH BULGE AND HIV In many sub-saharan African countries, declines in child mortality combined with a slow decline in fertility have resulted in
More informationHigh Level Regional Consultation for Policy Makers to Enhance Leadership in Planning the National HIV & AIDS Response. HIV Prevention (PM1S4)
High Level Regional Consultation for Policy Makers to Enhance Leadership in Planning the National HIV & AIDS Response HIV Prevention (PM1S4) Tomas Lundstrom UNAIDS RST/ESA Overview Prioritization Low level
More informationSix things you need to know
UNAIDS Report 2010 MDG 6 Six things you need to know about the AIDS response today UNAIDS Report 2010 MDG 6 Six things you need to know about the AIDS response today MDG6: Combat HIV/AIDS, Malaria and
More informationElements of Reproductive Health
SEXUAL& REPRODUCTIVE HEALTH and HIV/AIDS INTEGRATION: Issues for consideration Dr. Chris Baryomunsi, MP Parliament of Uganda Elements of Reproductive Health Safe motherhood Family Planning Prevention and
More informationincreased efficiency. 27, 20
Table S1. Summary of the evidence on the determinants of costs and efficiency in economies of scale (n=40) a. ECONOMETRIC STUDIES (n=9) Antiretroviral therapy (n=2) Scale was found to explain 48.4% of
More informationProgress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa
SUMMARY REPORT Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa January December 2012 Table of contents List of acronyms 2 Introduction 3 Summary
More informationPLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE
CHAPTER 2 PLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE 2.1 INTRODUCTION Achieving quality integrated HIV services at your health centre is dependant on good planning and management. This chapter
More informationMain global and regional trends
I N T R O D U C T I O N Main global and regional trends Promising developments have been seen in recent years in global efforts to address the AS epidemic, including increased access to effective treatment
More informationUse of Pre-exposure Prophylaxis (PrEP) in pregnancy for primary prevention of HIV infection in women
Use of Pre-exposure Prophylaxis (PrEP) in pregnancy for primary prevention of HIV infection in women Catherine Hankins MD PhD FRCPC CM Deputy Director, Science Amsterdam Institute for Global Health and
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationPrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?
PrEP Guidelines for the Ob/Gyn Megan J. Huchko, MD, MPH Obstetrics and Gynecology Update October 14, 2015 I have no financial or other conflicts of interest to declare Outline The Need for PrEP: HIV Treatment
More informationHIV In South Africa: Turning the Tide of the Epidemic
HIV In South Africa: Turning the Tide of the Epidemic Jean B. Nachega, MD, PhD Associate Professor Department of Epidemiology Pittsburgh University, Graduate School of Public Health E-mail: JBN16@PITT.EDU
More informationSex Work in Sub-Saharan Africa : Opportunities and Challenges
Sex Work in Sub-Saharan Africa : Opportunities and Challenges Dr Traore Isidore May 26, 2016 Definition of Sex Worker Female, male and transgender adults (18 years of age and above) who receive money or
More informationIs this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health
Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health Thirty years of AIDS July 3, 1981 A generation in the
More informationPEPFAR 3.0 Vision for an AIDS-Free Generation. Ambassador Deborah L. Birx, M.D. U.S. Department of State June 2015
PEPFAR 3.0 Vision for an AIDS-Free Generation Ambassador Deborah L. Birx, M.D. U.S. Department of State June 2015 PEPFAR s Evolution From Emergency Response to Sustainable Impact for an AIDS-free Generation
More informationCAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina
CAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina Overview Epidemiology of HIV in young people Rationale behind cash transfers Review completed
More informationThe global plan to eliminate mother to child transmission (emtct) of HIV: challenges in integration and of therapeutic strategies
Training Course in Sexual and Reproductive Health Research 2014 Module: Principles and Practice of Sexually Transmitted Infections Prevention and Care The global plan to eliminate mother to child transmission
More informationWHO HIV Drug Resistance Prevention and Assessment Strategy. Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team
WHO HIV Drug Resistance Prevention and Assessment Strategy Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team Eastern & Southern African Countries (ESA) 2 The HIV epidemic
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationBiomedical HIV Prevention & TaP Treatment as Prevention 2013
Biomedical HIV Prevention & TaP Treatment as Prevention 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationLinkages between Sexual and Reproductive Health and HIV
Linkages between Sexual and Reproductive Health and HIV Manjula Lusti-Narasimhan Department of Reproductive Health and Research World Health Organization The HIV pandemic 25 years 1981 2006 Rationale for
More informationHIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07
HIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07 Estimates of Per-Contact Risk of HIV Infection HIV TRANSMISSION SIGNIFICANT, LOW
More informationChildren and AIDS Fourth Stocktaking Report 2009
Children and AIDS Fourth Stocktaking Report 2009 The The Fourth Fourth Stocktaking Stocktaking Report, Report, produced produced by by UNICEF, UNICEF, in in partnership partnership with with UNAIDS, UNAIDS,
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More informationPre-exposure Prophylaxis and Primary Care
Pre-exposure Prophylaxis and Primary Care National Latino HIV and Hepatitis C Conference June 7 th, 2016 Allison Finkenbinder, MSN, WHNP-BC Denver Prevention Training Center Who s in the audience? Disclosures
More informationProgress in scaling up HIV prevention and treatment in sub-saharan Africa: 15 years, the state of AIDS
10 th International Workshop on HIV treatment, Pathogenesis and Prevention Research in Resource-Limited setting (INTEREST, 3-6 May, 2016) Progress in scaling up HIV prevention and treatment in sub-saharan
More informationModule 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs
Module 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with the basic concepts of
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationStart Free Stay Free AIDS Free progress report
Start Free Stay Free AIDS Free 217 progress report Copyright 217 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved. The designations employed and the presentation of the material
More informationProgress Report: Universal Access Target Setting in East and Southern Africa
Progress Report: Universal Access Target Setting in East and Report prepared by: Team for East & 15 September 2006 For all inquiries please contact Mark Stirling, Regional Director for Eastern and, at
More informationHIV / AIDS. Prevention In Our Lives
HIV / AIDS Prevention In Our Lives Prevention In Our Lives: Produced by the Treatment Action Campaign. Authors: Published: September 2010 Conte n t s Introduction: Statistics on HIV in South Africa 2 Why
More informationTowards an AIDS Free Generation
Informal Board Meeting 18 January, 2011 Towards an AIDS Free Generation Craig McClure Chief, HIV and AIDS Achieving an AIDS-Free Generation UNAIDS Getting to Zero UNICEF MTSP The Unite for Children, Unite
More informationThe Nexus Between 90/90/90 and Epidemic Control. Ambassador Deborah Birx IAS July 2018
The Nexus Between 90/90/90 and Epidemic Control Ambassador Deborah Birx IAS July 2018 What is the Global Goal for HIV? The HIV/AIDS SDG Goal: Control the HIV Pandemic by 2030 90/90/90 by 2020 and 95/95/95
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I 2011 Rationale for including this activity in the proposal The World Health Organization (WHO), the Joint United
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationColloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention
Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Julia Walsh MD, MSc Professor School of Public Health University of California Berkeley Objectives Cost-effectiveness
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationOverview of ARV-based prevention trials
Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical
More informationTreatment as Prevention
Optimizing the Impact of ART Treatment as Prevention A Made-in-BC Strategy to End the AIDS Pandemic Julio Montaner, OC, OBC, MD Professor of Medicine and Head, Division of AIDS, University of British Columbia
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationInvesting for Impact
Global Fund Strategic Framework: Investing for Impact M&E: Capturing data to improve services Workshop to Scale Up the Implementation of Collaborative TB/HIV Activities in Africa 10-11 April, 2013; Maputo,
More informationThe Beginning of the End of AIDS Diane V. Havlir, MD
The Beginning of the End of AIDS Diane V. Havlir, MD Professor of Medicine University of California, San Francisco AIDS: The Beginning Friedman-Kien, Color Atlas of AIDS AIDS: The Middle Number of people
More informationHIV in Women: A Global View of the HIV Epidemic
HIV in Women: A Global View of the HIV Epidemic George Schmid, M.D., M.Sc. Department of HIV/AIDS World Health Organization Geneva, Switzerland Schmidg@who.int Training Course in Sexual and Reproductive
More informationAchieving the 3 rd 90 in PEPFAR-supported countries:
Center for Global Health Achieving the 3 rd 90 in PEPFAR-supported countries: What will it take? Is it enough? Elliot Raizes, MD Division of Global HIV and TB Centers for Disease Control and Prevention
More informationRESEARCH. All Photos: Eric Bond/EGPAF,2017
RESEARCH All Photos: Eric Bond/EGPAF,2017 The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a recognized global leader in the fight to end pediatric HIV/AIDS through research, advocacy, and delivery
More informationOutline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012
HIV and Other Sexually Transmitted Infections Tanya Kowalczyk Mullins, MD, MS Division of Adolescent Medicine Cincinnati Children s Hospital Medical Center Outline Epidemiology of select STIs and HIV STIs
More information